Therapeutic recommendation for young cancer patients remains insufficient, forcing physicians to regularly prescribe treatments that are only permitted for adults. The study by French Sacha, presented this week at the World Cancer Congress organized by the American Society of Clinical Oncology (ASCO) in Chicago, is the first to collect data on the safety and efficacy of these prescriptions.
When standard treatments are ineffective or otherwise ineffective, young patients may be able to benefit from therapeutic innovations that have proliferated in the field of oncology in recent years. However, few are authorized to treat children, most often due to a lack of data in pediatric patients. Therefore, access to innovative therapies is available through clinical trials, but up to 40% to 50% of children with treatment failure are not eligible. In this case, the National Agency for Drug Safety (ANSM) authorizes…
Source: Le Figaro
